Precision Diagnostics

Global Precision Diagnostics Market to Reach US$49.8 Billion by 2030

The global market for Precision Diagnostics estimated at US$18.2 Billion in the year 2024, is expected to reach US$49.8 Billion by 2030, growing at a CAGR of 18.3% over the analysis period 2024-2030. Genetic Tests, one of the segments analyzed in the report, is expected to record a 20.1% CAGR and reach US$26.3 Billion by the end of the analysis period. Growth in the Direct to Consumer Tests segment is estimated at 14.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.0 Billion While China is Forecast to Grow at 24.3% CAGR

The Precision Diagnostics market in the U.S. is estimated at US$5.0 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$11.3 Billion by the year 2030 trailing a CAGR of 24.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 13.4% and 16.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.6% CAGR.

Global Precision Diagnostics Market – Key Trends & Drivers Summarized

Why Is Precision Diagnostics Reshaping the Future of Healthcare?

Precision diagnostics refers to a set of advanced medical technologies that enable highly accurate disease detection, often at the molecular or genetic level. Unlike traditional diagnostic methods, precision diagnostics focuses on individual variability in genes, lifestyle, and environment to tailor diagnosis and treatment strategies to each patient. This shift allows for earlier disease identification, better risk stratification, and more personalized care pathways, significantly improving patient outcomes and reducing treatment inefficiencies.

The increasing global incidence of complex diseases such as cancer, cardiovascular conditions, and autoimmune disorders has accelerated the demand for more sophisticated diagnostic tools. As healthcare systems evolve toward prevention and value-based care, precision diagnostics is emerging as a cornerstone of this transformation. Its role in early detection, prognosis, and monitoring is not only reducing disease burden but also enabling timely intervention, which is especially critical for chronic and life-threatening conditions.

How Are Technological Advancements and Consumer Expectations Influencing the Market?

Technological innovation is rapidly advancing the precision diagnostics landscape. The growing capabilities of genomic sequencing, molecular profiling, and biomarker analysis have made it possible to detect diseases at their earliest and most treatable stages. Tools powered by artificial intelligence and machine learning are now enhancing pattern recognition, automating data interpretation, and supporting real-time clinical decision-making. These breakthroughs are expanding the scope and speed of diagnostics, making them more effective and scalable.

At the same time, consumer behavior is shaping how precision diagnostics are being designed and delivered. Today’s patients are more health-literate, data-conscious, and proactive about personalized health solutions. There`s growing interest in non-invasive testing options such as liquid biopsies, wearable health devices, and home-based test kits. This shift is pushing healthcare providers and diagnostics companies to deliver more user-centric experiences that combine accuracy, speed, convenience, and privacy. These evolving expectations are influencing product development, clinical workflows, and the overall positioning of precision diagnostics in modern medicine.

<">The Growth in the Precision Diagnostics Market Is Driven by Several Factors……

The growth in the precision diagnostics market is driven by several factors, starting with the expanding application of diagnostic technologies across oncology, cardiology, neurology, and infectious diseases. The ability to identify actionable genetic mutations and biomarkers is enabling clinicians to tailor therapies and monitor treatment effectiveness with greater precision. This is particularly crucial in cancer treatment, where targeted therapies are becoming standard practice.

Another major driver is the reduction in cost and complexity of advanced diagnostic technologies, making them more accessible to clinics, labs, and even consumers. The integration of diagnostics with electronic health records, clinical decision support tools, and personalized treatment algorithms is enhancing care coordination and reducing misdiagnoses. Additionally, rising investment in health innovation and institutional support for personalized medicine is fostering the development and deployment of next-generation diagnostic platforms. Collectively, these factors are positioning precision diagnostics as a transformative force in the future of healthcare.

SCOPE OF STUDY:

The report analyzes the Precision Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Test Type (Genetic Tests, Direct to Consumer Tests, Esoteric Tests, Other Test Types); Application (Oncology Application, Respiratory Diseases Application, Skin Diseases Application, CNS Disorders Application, Immunology Application, Genetic Diseases Application, Other Applications); End-Use (Clinical Laboratories End-Use, Hospitals End-Use, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• Abbott Laboratories
• Agilent Technologies Inc.
• Bayer AG
• Becton, Dickinson and Company
• bioMérieux SA
• Danaher Corporation
• Exact Sciences Corporation
• F. Hoffmann-La Roche Ltd
• Guardant Health
• Hologic, Inc.
• Illumina, Inc.
• Koninklijke Philips N.V.
• Lantheus Holdings, Inc.
• Myriad Genetics, Inc.
• Novartis AG
• PerkinElmer, Inc.
• QIAGEN N.V.
• Siemens Healthineers AG
• Swiss Precision Diagnostics GmbH
• Thermo Fisher Scientific Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.